Next-generation therapeutic development for neurogenic orthostatic hypotension

Recent updates in autonomic research: a focus on new technologies with high-resolution procedures to study sympathetic nerve activity, plasma proteomic profiling and POTS, and non-invasive neuromodulation with focused ultrasound, 2023, Jaquie R Baker et al

Neurogenic orthostatic hypotension (NOH) is a chronic condition associated with cardiovascular disease and reduced quality of life [1, 2]. NOH occurs due to failure of the autonomic nervous system to reflexively control sympathetic nervous system (SNS) activity to the vasculature resulting in hemodynamic instability.

On assuming the upright position, people with NOH experience persistent drops in blood pressure (BP) (≥ 20/10 mmHg) often accompanied by debilitating symptoms. NOH affects the elderly and those with a variety of conditions including neurodegenerative diseases (e.g., Parkinson’s disease, multiple system atrophy), autonomic neuropathies, and neural injury (e.g., spinal cord injury [SCI]) [1, 2].

Current therapies are often just band-aids for people with moderate-to-severe NOH, leaving many still looking and hoping for new treatments.

https://link.springer.com/article/10.1007/s10286-023-00924-2